{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:26:07Z","timestamp":1783103167119,"version":"3.54.6"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ijcard.2013.06.069","type":"journal-article","created":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T14:45:57Z","timestamp":1375109157000},"page":"1811-1818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies"],"prefix":"10.1016","volume":"168","author":[{"given":"Esther M.M.","family":"Ooi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Hugh R.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2013.06.069_bb0005","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/hrt.2003.022764","article-title":"Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia","volume":"12","author":"Neil","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"5","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0015","first-page":"893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"6807","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0020","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0025","first-page":"1769","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"14","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"2","author":"Watts","year":"2011","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"5","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0040","series-title":"The Molecular and Metabolic Basis of Inhabited Disease","first-page":"1981","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"1999"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0045","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"12","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2011.07.014","article-title":"Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box","volume":"1","author":"Chan","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOL.0b013e328353ef07","article-title":"Reverse cholesterol transport in familial hypercholesterolemia","author":"Guerin","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0065","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"11","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/hrt.2010.220699","article-title":"CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia","volume":"14","author":"Neefjes","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2012.10.032","article-title":"Statin treatment of children with familial hypercholesterolemia\u2014trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?","author":"Vuorio","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-2275(20)37589-1","article-title":"Role of cholesterol in regulating apolipoprotein B secretion by the liver","volume":"3","author":"Thompson","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0021-9150(99)00282-8","article-title":"Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm","volume":"2","author":"Sniderman","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.ATV.13.5.629","article-title":"Substrate delivery as a determinant of hepatic apoB secretion","volume":"5","author":"Sniderman","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(01)00012-5","article-title":"Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism","volume":"3","author":"Barrett","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0100","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0022-2275(20)41088-0","article-title":"Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells","volume":"12","author":"Avramoglu","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI6246","article-title":"Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL","volume":"7","author":"Horton","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI8623","article-title":"The role of the LDL receptor in apolipoprotein B secretion","volume":"4","author":"Twisk","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0115","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1073\/pnas.072557199","article-title":"Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B","volume":"7","author":"Gillian-Daniel","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0120","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1074\/jbc.M710457200","article-title":"Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB","volume":"17","author":"Blasiole","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0125","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/hep.25871","article-title":"\u2018JD\u2019 iPS cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia","author":"Cayo","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0130","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1073\/pnas.80.19.6096","article-title":"Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits","volume":"19","author":"Hornick","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.ATV.0000018304.30943.06","article-title":"Normal production rate of apolipoprotein B in LDL receptor-deficient mice","volume":"6","author":"Millar","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Pt 1","key":"10.1016\/j.ijcard.2013.06.069_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2362.1980.tb02076.x","article-title":"Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects","volume":"2","author":"Janus","year":"1980","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/01.ATV.14.4.501","article-title":"ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm","volume":"4","author":"Fisher","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0021-9150(94)05430-Q","article-title":"Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study","volume":"1","author":"Cummings","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-2275(20)33899-2","article-title":"VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100","volume":"2","author":"Zulewski","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0160","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1194\/jlr.M300448-JLR200","article-title":"Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation","volume":"5","author":"Tremblay","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0165","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.ATV.0000155323.18856.a2","article-title":"Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production","volume":"3","author":"Millar","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0170","first-page":"361","article-title":"Non-steady-state studies of low-density-liproprotein turnover in familial hypercholesterolaemia","volume":"4","author":"Thompson","year":"1977","journal-title":"Clin Sci Mol Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0021-9150(97)00173-1","article-title":"Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect","volume":"2","author":"Pfohl","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0180","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0022-2275(20)37487-3","article-title":"Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia","volume":"11","author":"Parhofer","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0185","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0026-0495(98)90063-4","article-title":"Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics","volume":"4","author":"Barrett","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0190","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/S0022-2275(20)37290-4","article-title":"Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach","volume":"10","author":"Pietzsch","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0195","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1161\/01.ATV.17.2.348","article-title":"Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs","volume":"2","author":"Schaefer","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0200","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"8","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCGENETICS.111.960948","article-title":"Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo","volume":"1","author":"Tada","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"10.1016\/j.ijcard.2013.06.069_bb0210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0215","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"23","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0220","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"6","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0225","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9149(00)01429-6","article-title":"Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia","volume":"5","author":"Hopkins","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0230","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"21","author":"Seed","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0235","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia","volume":"2","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0240","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"2","author":"Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0245","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0021-9150(91)90025-X","article-title":"Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects","volume":"2\u20133","author":"Knight","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0250","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0021-9150(92)90279-P","article-title":"Lipoprotein(a) in subjects with familial defective apolipoprotein B100","volume":"2\u20133","author":"Perombelon","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0255","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2362.1993.tb00966.x","article-title":"In vivo kinetics of lipoprotein(a) in homozygous Watanabe heritable hyperlipidaemic rabbits","volume":"9","author":"Liu","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0260","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2362.1993.tb00736.x","article-title":"Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis","volume":"12","author":"Lasuncion","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0265","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"11","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0270","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157016111795495585","article-title":"Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol","volume":"3","author":"Nordestgaard","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0275","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/157016111795495549","article-title":"Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement","volume":"3","author":"Kolovou","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157016111795495530","article-title":"Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis","volume":"3","author":"Mihas","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2796.2003.01070.x","article-title":"Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia","volume":"2","author":"Sauvage Nolting","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0290","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijcard.2010.08.009","article-title":"Familial hypercholesterolemia and triglyceride metabolism","volume":"3","author":"Kolovou","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0295","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2362.2012.02700.x","article-title":"Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia","author":"Tada","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0300","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1161\/01.CIR.97.8.729","article-title":"A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia","volume":"8","author":"Wittekoek","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"2","author":"Johansen","year":"2011","journal-title":"J Lipid Res"},{"issue":"9874","key":"10.1016\/j.ijcard.2013.06.069_bb0310","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case\u2013control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0315","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0320","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"9","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0325","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"20","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/euhj.2000.2408","article-title":"Importance of HDL cholesterol levels and the total\/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia","volume":"6","author":"Real","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0335","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1023\/A:1005325911665","article-title":"Analysis of CBS alleles in Czech and Slovak patients with homocystinuria: report on three novel mutations E176K, W409X and 1223+37 del99","volume":"3","author":"Kozich","year":"1997","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14737159.7.1.45","article-title":"Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment","volume":"1","author":"Seo","year":"2007","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0345","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9150(98)00271-8","article-title":"Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases","volume":"1","author":"Tsai","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0350","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-8703(03)00501-5","article-title":"The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease","volume":"6","author":"Carlquist","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0355","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.ejhg.5201426","article-title":"TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia","volume":"7","author":"Mohrschladt","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0360","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0022-2275(20)33394-0","article-title":"Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study","volume":"8","author":"Frenais","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0365","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/01.ATV.20.7.1796","article-title":"Increased production of HDL ApoA-I in homozygous familial defective ApoB-100","volume":"7","author":"Schaefer","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0370","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2006.02.023","article-title":"Association of heterozygous familial hypercholesterolemia with smaller HDL particle size","volume":"2","author":"Hogue","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0375","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0021-9150(89)90127-5","article-title":"Kinetics of HDL-apo A-I in the WHHL rabbit, an animal model of familial hypercholesterolemia","volume":"2\u20133","author":"Saku","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0380","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.ATV.12.7.843","article-title":"In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia","volume":"7","author":"Schaefer","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0385","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/ATVBAHA.111.227181","article-title":"Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia","volume":"7","author":"Bellanger","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0390","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jacc.2005.06.080","article-title":"High-density lipoprotein function recent advances","volume":"10","author":"Ansell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0395","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1194\/jlr.M024141","article-title":"Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia","volume":"4","author":"Orsoni","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0400","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.clinthera.2010.04.014","article-title":"Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial","volume":"4","author":"Huijgen","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0405","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosissup.2004.08.025","article-title":"Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983","volume":"3","author":"Bilheimer","year":"2004","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0410","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11886-011-0219-9","article-title":"Familial hypercholesterolemia: present and future management","volume":"6","author":"Sjouke","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0167-5273(02)00420-5","article-title":"Familial hypercholesterolemia\u2014improving treatment and meeting guidelines","volume":"1","author":"Hopkins","year":"2003","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0420","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"9858","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0425","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"12","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0430","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"19","author":"Dias","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0435","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"20","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0440","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"4","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0445","doi-asserted-by":"crossref","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0450","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"2","author":"Lindholm","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0455","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"33","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"1","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0465","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"5","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0470","doi-asserted-by":"crossref","first-page":"12086","DOI":"10.3390\/molecules171012086","article-title":"c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-alpha pathway to PCSK9-mediated LDLR degradation pathway","volume":"10","author":"Xu","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0475","doi-asserted-by":"crossref","first-page":"43492","DOI":"10.1074\/jbc.M112.394023","article-title":"The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway","author":"Luna Saavedra","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0480","first-page":"1","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0485","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/ATVBAHA.110.204040","article-title":"Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control","volume":"7","author":"Herbert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0490","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"2","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0495","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/MOL.0b013e32834622b5","article-title":"Unexpected roles for PCSK9 in lipid metabolism","volume":"3","author":"Soutar","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0500","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0505","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","article-title":"LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor","volume":"5936","author":"Zelcer","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0510","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"19","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0515","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0520","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"2","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0525","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"9860","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0530","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"4","author":"Carlson","year":"1989","journal-title":"J Intern Med"},{"issue":"17","key":"10.1016\/j.ijcard.2013.06.069_bb0535","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.2174\/1381612811319170022","article-title":"The promise of Cholesteryl Ester Transfer Protein (CETP) inhibition in the treatment of cardiovascular disease","volume":"19","author":"Bochem","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0540","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"10","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0545","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"15","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0550","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2012.01.045","volume":"23","author":"Michos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0555","first-page":"2255","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"24","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ijcard.2013.06.069_bb0560","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0565","first-page":"309","article-title":"n\u22123 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"4","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0570","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n\u22123 fatty acids and cardiovascular events after myocardial infarction","volume":"21","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0575","first-page":"463","article-title":"Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial","volume":"4","author":"Macchia","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0580","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.2012.28733","article-title":"Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial","volume":"19","author":"Mozaffarian","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0585","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"9567","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0590","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.jacc.2012.07.045","article-title":"Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects","volume":"20","author":"Johannsen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0595","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1194\/jlr.R024513","article-title":"Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?","volume":"9","author":"Kunnen","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0600","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.03.004","article-title":"Novel HDL-based therapeutic agents","volume":"1","author":"Joy","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0605","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","article-title":"RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo","volume":"23","author":"Bailey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0610","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.transci.2011.11.016","article-title":"Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles","volume":"1","author":"Hovland","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"2","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0620","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.transci.2009.05.013","article-title":"26years of LDL\u2013apheresis: a review of experience","volume":"1","author":"Borberg","year":"2009","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0625","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacl.2010.08.013","article-title":"Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis","volume":"5","author":"Hemphill","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0630","doi-asserted-by":"crossref","first-page":"E939","DOI":"10.1152\/ajpendo.00031.2011","article-title":"Effects of exercise on VLDL-triglyceride oxidation and turnover","volume":"5","author":"Sondergaard","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0635","first-page":"2854","article-title":"Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men","volume":"8","author":"Riches","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0640","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2337\/dc05-2530","article-title":"Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia","volume":"5","author":"Rana","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0645","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2009.04.002","article-title":"Where are we with probucol: a new life for an old drug?","volume":"1","author":"Yamashita","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0650","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOL.0b013e32832aee68","article-title":"Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues","volume":"3","author":"Stocker","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0655","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5551\/jat.12807","article-title":"Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia","volume":"7","author":"Inagaki","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0660","doi-asserted-by":"crossref","first-page":"16H","DOI":"10.1016\/0002-9149(86)90430-3","article-title":"Studies on the mechanism of action of probucol","volume":"16","author":"Steinberg","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0665","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0021-9150(81)90117-9","article-title":"Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis","volume":"1\u20132","author":"Nestel","year":"1981","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2013.06.069_bb0670","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5551\/jat.E610","article-title":"Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan","volume":"6","author":"Yamashita","year":"2008","journal-title":"J Atheroscler Thromb"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527313011248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527313011248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:45:07Z","timestamp":1759092307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527313011248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0167527313011248"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2013.06.069","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2013.06.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}